APDN vs. SPCB, CRKN, AREB, GWAV, LGMK, JCSE, MOB, MWG, HUBC, and DGLY
Should you be buying Applied DNA Sciences stock or one of its competitors? The main competitors of Applied DNA Sciences include SuperCom (SPCB), Crown ElectroKinetics (CRKN), American Rebel (AREB), Greenwave Technology Solutions (GWAV), LogicMark (LGMK), JE Cleantech (JCSE), Mobilicom (MOB), Multi Ways (MWG), HUB Cyber Security (HUBC), and Digital Ally (DGLY). These companies are all part of the "industrial products" sector.
SuperCom (NASDAQ:SPCB) and Applied DNA Sciences (NASDAQ:APDN) are both small-cap industrial products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations.
Applied DNA Sciences has a consensus price target of $7.00, indicating a potential upside of 178.88%. Given SuperCom's higher probable upside, analysts plainly believe Applied DNA Sciences is more favorable than SuperCom.
In the previous week, Applied DNA Sciences had 2 more articles in the media than SuperCom. MarketBeat recorded 9 mentions for Applied DNA Sciences and 7 mentions for SuperCom. Applied DNA Sciences' average media sentiment score of 0.45 beat SuperCom's score of 0.38 indicating that SuperCom is being referred to more favorably in the media.
SuperCom received 53 more outperform votes than Applied DNA Sciences when rated by MarketBeat users. However, 59.23% of users gave Applied DNA Sciences an outperform vote while only 58.57% of users gave SuperCom an outperform vote.
47.8% of SuperCom shares are owned by institutional investors. Comparatively, 22.2% of Applied DNA Sciences shares are owned by institutional investors. 18.3% of SuperCom shares are owned by insiders. Comparatively, 10.3% of Applied DNA Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
SuperCom has a net margin of -9.79% compared to SuperCom's net margin of -222.33%. Applied DNA Sciences' return on equity of 91.58% beat SuperCom's return on equity.
SuperCom has higher revenue and earnings than Applied DNA Sciences.
SuperCom has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500. Comparatively, Applied DNA Sciences has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.
Summary
SuperCom beats Applied DNA Sciences on 10 of the 16 factors compared between the two stocks.
Get Applied DNA Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APDN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Applied DNA Sciences Competitors List
Related Companies and Tools
